<DOC>
	<DOCNO>NCT00003979</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness CHS 828 treat patient solid tumor .</brief_summary>
	<brief_title>CHS 828 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose oral CHS 828 patient solid tumor . - Determine qualitative quantitative toxic effect regimen patient . - Determine safe dose regimen phase II evaluation . - Determine pharmacokinetic profile regimen patient . - Determine antitumor activity patient . OUTLINE : Patients receive oral CHS 828 every 3 week . Treatment continue least 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos CHS 828 maximum tolerate dose ( MTD ) reach . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A total 30 patient accrue study within 12 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor amenable standard therapy No symptomatic brain leptomeningeal involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Other liver function test great 2 time upper limit normal ( unless relate liver metastasis ) Renal : Creatinine great 1.4 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No active bacterial infection No nonmalignant disease No alcoholism , drug addiction , psychiatric disorder Able take oral medication PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas ) No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy ( 6 week since extensive radiotherapy ) No concurrent radiotherapy ( except palliative radiotherapy ) Surgery : Not specify Other : No concurrent investigational drug No concurrent antitumor drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>